It is noteworthy whether the first combination option of targeted anticancer drugs to enter insurance coverage in the first-line lung cancer therapy will be possible.

According to related industries, first-line therapy for non-small cell lung cancer (NSCLC) VEGF receptor 2 antagonist Cyramza (Ramucirumab) and epithelial cell growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tarceva (Erlotinib), It is expected that the combination therapy of Tarceva (Erlotinib) will be presented to the Review Committee for Cancer Diseases of the HIRA this year, which will be held next week.

The combination therapy of the two drugs was approved by the EMA in January and the FDA in June. The new